Skip to main content
    A

    Aprea Therapeutics Inc (APRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.41
    -0.01 (-2.38%)

    Market Cap: $5.91M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Aprea Therapeutics Inc (APRE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Aprea Therapeutics reported revenue of $285.76K for the fiscal year ended Dec 31, 2025, down 81.0% from the year before. That year, net income was -$12.60M with a net margin of -4409.2%, operating cash flow was -$12.89M and free cash flow was -$12.89M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$4.81M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$285.76K-81.0%100.0%-4631.1%-4409.2%
    Dec 2024$1.50M+157.6%100.0%-953.0%-862.4%
    Dec 2023$583.23KN/A100.0%-2652.8%-2449.6%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2013$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2013 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2013
    Revenue$285.76K$1.50M$583.23K$0$0$0$0$0$0$0
    Cost of revenue$0$0$0$0$0$0$0$0$7.93K$0
    Gross profit$285.76K$1.50M$583.23K$0$0$0$0$0-$7.93K$0
    Research and development$7.04M$9.36M$7.63M$92.42M$23.90M$37.88M$20.95M$14.19M$13.39M$0
    Operating income-$13.23M-$14.32M-$15.47M-$113.39M-$37.45M-$52.81M-$29.54M-$16.49M-$15.85M-$246.49K
    Net income-$12.60M-$12.96M-$14.29M-$112.66M-$37.13M-$53.48M-$28.06M-$15.53M-$15.19M-$436.21K
    EBITDA-$13.23M-$14.23MN/A-$112.92M-$36.86MN/A-$28.05M-$15.52M-$15.18MN/A
    Fiscal years ended Dec 2013 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$3.34K$1.85K$118.11K$162.46K$205.82K$354.62K$561.57K$380.57K$14.07K
    Gross profit$0$0$0$3.34K$1.85K$118.11K$162.46K$205.82K$354.62K$561.57K$380.57K$14.07K
    Operating income-$5.17M-$4.03M-$3.43M-$2.64M-$3.12M-$3.39M-$4.09M-$3.23M-$4.10M-$3.85M-$3.15M-$3.67M
    Net income-$4.81M-$3.59M-$3.29M-$2.46M-$2.97M-$3.24M-$3.93M-$2.89M-$3.78M-$3.47M-$2.81M-$3.44M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $14.60M were 91.7% of total assets of $15.93M, against total liabilities of $2.76M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2013
    Total assets$15.93M$23.98M$22.65M$30.16M$56.82M$92.81M$133.61M$66.02M$24.76MN/A
    Current assets$15.56M$23.58M$22.52M$30.15M$56.58M$92.42M$133.04M$66.00M$24.73MN/A
    Cash and equivalents$14.60M$22.85M$21.61M$28.79M$53.08M$89.02M$130.09M$65.68M$24.40MN/A
    Total liabilities$2.76M$3.36M$4.39M$3.20M$7.32M$15.41M$9.36M$4.87M$60.53M$5.70M
    Short-term debtN/AN/AN/AN/A$190.47K$256.31K$242.33K$0$0$1.48M
    Shareholder equity$12.44M$19.31M$16.95M$25.64M$49.51M$77.40M$124.24M-$51.44M-$35.77MN/A
    Fiscal years ended Dec 2013 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$38.81M$42.29M$47.61M$15.93M$14.32M$17.31M$20.22M$23.98M$26.89M$29.96M$33.20M$22.65M
    Total liabilities$3.97M$3.09M$5.30M$3.49M$2.68M$3.17M$3.36M$4.67M$3.64M$3.09M$2.97M$4.39M
    Cash and equivalents$37.85M$41.23M$46.47M$14.60M$13.72M$16.53M$19.28M$22.85M$26.25M$28.69M$32.37M$21.61M
    Shareholder equity$34.11M$38.47M$41.59M$12.44M$10.91M$13.41M$15.55M$19.31M$21.95M$25.56M$28.92M$18.26M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$12.89M-$13.56M-$12.18M-$25.01M-$37.69M-$41.80M-$26.71M-$15.25M-$14.00M
    Capital expenditures$0$15.48K$93.09K$0$0$25.71K$30.90K$3.70K$3.70K
    Free cash flow-$12.89M-$13.57M-$12.27M-$25.01M-$37.69M-$41.83M-$26.74M-$15.25M-$14.01M
    Share repurchases$407.46K$1.32M$648.93K$0$0N/AN/AN/AN/A
    Investing cash flow$0-$15.48K-$93.09K$0$0-$25.71K-$30.90K-$3.70K-$3.70K
    Financing cash flow$4.64M$14.82M$5.14M$682.97K$1.75M$150.95K$92.58M$56.37M$23.34M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$3.73M-$3.28M-$2.76M-$2.96M-$3.17M-$3.13M-$3.63M-$3.51M-$2.47M-$3.64M-$3.94M-$3.74M
    Capital expenditures$1N/A$0$0N/A$0$0N/A$209$7.50K$7.98K$7.15K
    Free cash flow-$3.73MN/A-$2.76M-$2.96MN/A-$3.13M-$3.63MN/A-$2.47M-$3.65M-$3.94M-$3.75M
    Last 12 quarters

    Frequently Asked Questions About APRE

    What is Aprea Therapeutics' annual revenue?

    Aprea Therapeutics reported revenue of $285.76K for the fiscal year ended Dec 31, 2025.

    How fast is Aprea Therapeutics' revenue growing?

    Revenue was down 81.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Aprea Therapeutics profitable?

    No. Aprea Therapeutics reported net income of -$12.60M for the fiscal year ended Dec 31, 2025, with a net margin of -4409.2%.

    How much free cash flow does APRE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$12.89M minus capital expenditures of $0 produced free cash flow of -$12.89M.

    How much debt does Aprea Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $14.60M.